Trial Profile
A pivotal,Phase 3 trial of oral and intravenous formulations of MRX-1 to treat acute bacterial skin and skin structure infections (ABSSSI).
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 07 Oct 2016
Price :
$35
*
At a glance
- Drugs Contezolid (Primary) ; Contezolid (Primary)
- Indications Bacterial infections; Skin and soft tissue infections
- Focus Registrational; Therapeutic Use
- 07 Oct 2016 New trial record